• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

估算肾小球滤过率在慢性肾脏病中的应用:对基于估算值预测肾脏病个体结局的批判性评价。

Estimated Glomerular Filtration Rate in Chronic Kidney Disease: A Critical Review of Estimate-Based Predictions of Individual Outcomes in Kidney Disease.

机构信息

Fresenius Medical Care, Cegléd Dialysis Center, Törteli u 1-3, 2700 Cegléd, Hungary.

Department of Medicine, St. Rókus Hospital, Rókus u 10, 6500 Baja, Hungary.

出版信息

Toxins (Basel). 2022 Feb 8;14(2):127. doi: 10.3390/toxins14020127.

DOI:10.3390/toxins14020127
PMID:35202154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8875627/
Abstract

Chronic kidney disease (CKD) is generally regarded as a final common pathway of several renal diseases, often leading to end-stage kidney disease (ESKD) and a need for renal replacement therapy. Estimated GFR (eGFR) has been used to predict this outcome recognizing its robust association with renal disease progression and the eventual need for dialysis in large, mainly cross-sectional epidemiological studies. However, GFR is implicitly limited as follows: (1) GFR reflects only one of the many physiological functions of the kidney; (2) it is dependent on several non-renal factors; (3) it has intrinsic variability that is a function of dietary intake, fluid and cardiovascular status, and blood pressure especially with impaired autoregulation or medication use; (4) it has been shown to change with age with a unique non-linear pattern; and (5) eGFR may not correlate with GFR in certain conditions and disease states. Yet, many clinicians, especially our non-nephrologist colleagues, tend to regard eGFR obtained from a simple laboratory test as both a valid reflection of renal function and a reliable diagnostic tool in establishing the diagnosis of CKD. What is the validity of these beliefs? This review will critically reassess the limitations of such single-focused attention, with a particular focus on inter-individual variability. What does science actually tell us about the usefulness of eGFR in diagnosing CKD?

摘要

慢性肾脏病(CKD)通常被认为是多种肾脏疾病的共同终末途径,常导致终末期肾病(ESKD)和需要肾脏替代治疗。估计肾小球滤过率(eGFR)已被用于预测这一结果,因为它与肾脏疾病进展以及最终需要透析具有很强的相关性,在大型、主要是横断面的流行病学研究中得到了证实。然而,GFR 受到以下因素的限制:(1)GFR 仅反映肾脏的许多生理功能之一;(2)它依赖于几个非肾脏因素;(3)它具有内在的可变性,是饮食摄入、液体和心血管状态以及血压的函数,特别是在自动调节受损或使用药物时;(4)已经表明它会随年龄而变化,具有独特的非线性模式;(5)eGFR 在某些情况下可能与 GFR 不相关,并且在某些疾病状态下也可能不相关。然而,许多临床医生,尤其是我们的非肾病学同事,往往将简单实验室检测获得的 eGFR 视为肾功能的有效反映,并且是诊断 CKD 的可靠诊断工具。这些信念的有效性如何?这篇综述将批判性地重新评估这种单一焦点的局限性,特别是个体间的可变性。科学实际上告诉我们什么关于 eGFR 在诊断 CKD 中的有用性?

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8941/8875627/4f6f2fc38e99/toxins-14-00127-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8941/8875627/4f6f2fc38e99/toxins-14-00127-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8941/8875627/4f6f2fc38e99/toxins-14-00127-g001.jpg

相似文献

1
Estimated Glomerular Filtration Rate in Chronic Kidney Disease: A Critical Review of Estimate-Based Predictions of Individual Outcomes in Kidney Disease.估算肾小球滤过率在慢性肾脏病中的应用:对基于估算值预测肾脏病个体结局的批判性评价。
Toxins (Basel). 2022 Feb 8;14(2):127. doi: 10.3390/toxins14020127.
2
Sex and Glomerular Filtration Rate Trajectories in Children.儿童的性别与肾小球滤过率轨迹。
Clin J Am Soc Nephrol. 2020 Mar 6;15(3):320-329. doi: 10.2215/CJN.08420719. Epub 2020 Feb 28.
3
Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study.非白蛋白尿性慢性肾脏病向终末期肾病进展的风险:CRIC(慢性肾功能不全队列)研究。
Am J Kidney Dis. 2018 Nov;72(5):653-661. doi: 10.1053/j.ajkd.2018.02.364. Epub 2018 May 18.
4
Acid retention in chronic kidney disease is inversely related to GFR.在慢性肾脏病中,酸的保留与 GFR 呈负相关。
Am J Physiol Renal Physiol. 2018 May 1;314(5):F985-F991. doi: 10.1152/ajprenal.00463.2017. Epub 2018 Jan 3.
5
A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.一种统一的肾小球滤过率估计方法:NKF-ASN 工作组关于重新评估种族在诊断肾脏疾病中的纳入的建议。
Am J Kidney Dis. 2022 Feb;79(2):268-288.e1. doi: 10.1053/j.ajkd.2021.08.003. Epub 2021 Sep 23.
6
Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study.镰状细胞病患者估算肾小球滤过率的逐渐下降:一项观察性队列研究。
Am J Kidney Dis. 2019 Jul;74(1):47-55. doi: 10.1053/j.ajkd.2018.12.027. Epub 2019 Feb 21.
7
Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.慢性肾脏病5期的保守治疗:血管紧张素转换酶抑制剂的作用
J Nephrol. 2016 Dec;29(6):809-815. doi: 10.1007/s40620-016-0290-9. Epub 2016 Mar 25.
8
Association between serum Na-Cl level and renal function decline in chronic kidney disease: results from the chronic kidney disease Japan cohort (CKD-JAC) study.慢性肾脏病患者血清钠-氯水平与肾功能下降的关联:日本慢性肾脏病队列(CKD-JAC)研究结果
Clin Exp Nephrol. 2019 Feb;23(2):215-222. doi: 10.1007/s10157-018-1631-x. Epub 2018 Aug 24.
9
Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.慢性肾脏病队列研究(CRIC):肾脏疾病结局与慢性肾脏病风险因素的相关性研究。
Am J Kidney Dis. 2014 Feb;63(2):236-43. doi: 10.1053/j.ajkd.2013.08.028. Epub 2013 Oct 30.
10
Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies.老年患者慢性肾脏病进展的性别差异:4 项队列研究的汇总分析。
Am J Kidney Dis. 2020 Jan;75(1):30-38. doi: 10.1053/j.ajkd.2019.05.019. Epub 2019 Aug 10.

引用本文的文献

1
Hemodialysis pathway types influence wound healing complications and survival in end-stage renal disease patients in a retrospective cohort study.在一项回顾性队列研究中,血液透析通路类型会影响终末期肾病患者的伤口愈合并发症及生存率。
Sci Rep. 2025 May 15;15(1):16866. doi: 10.1038/s41598-025-01602-1.
2
Association of estimated glomerular filtration rate with proliferative diabetic retinopathy: a systematic review and meta-analysis.估算肾小球滤过率与增殖性糖尿病视网膜病变的关联:一项系统评价和荟萃分析。
Int Urol Nephrol. 2025 May 4. doi: 10.1007/s11255-025-04547-6.
3
The Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) to HDL-C Ratio (NHHR) and Its Association with Chronic Kidney Disease in Chinese Adults with Type 2 Diabetes: A Preliminary Study.

本文引用的文献

1
Race-Free Equations for eGFR: Comparing Effects on CKD Classification.估算肾小球滤过率(eGFR)的无种族差异方程:对慢性肾脏病(CKD)分类的影响比较
J Am Soc Nephrol. 2021 Aug;32(8):1868-1870. doi: 10.1681/ASN.2021020224.
2
Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study.一项基于德国人群的研究中估算肾小球滤过率的分布及其随年龄丢失的决定因素。
Sci Rep. 2021 May 13;11(1):10165. doi: 10.1038/s41598-021-89442-7.
3
Subjective global assessment of nutrition, dialysis quality, and the theory of the scientific method in Nephrology practice.
非高密度脂蛋白胆固醇(Non-HDL-C)与高密度脂蛋白胆固醇比值(NHHR)及其与中国成年2型糖尿病患者慢性肾脏病的关联:一项初步研究
Nutrients. 2025 Mar 24;17(7):1125. doi: 10.3390/nu17071125.
4
The effectiveness of antioxidant agents in delaying progression of diabetic nephropathy: A systematic review of randomized controlled trials.抗氧化剂在延缓糖尿病肾病进展中的有效性:随机对照试验的系统评价
Bioimpacts. 2024 Jun 19;15:30129. doi: 10.34172/bi.30129. eCollection 2025.
5
Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome.评估儿童期抗中性粒细胞胞浆抗体相关性血管炎中的肾脏疾病:疾病进程、结局及结局预测因素
Arthritis Rheumatol. 2025 May;77(5):606-614. doi: 10.1002/art.43071. Epub 2025 Jan 14.
6
Rate of decline in kidney function with age: a systematic review.肾功能随年龄下降的速率:一项系统综述。
BMJ Open. 2024 Nov 27;14(11):e089783. doi: 10.1136/bmjopen-2024-089783.
7
Development and validation of a chronic kidney disease progression model using patient-level simulations.利用患者水平模拟开发和验证慢性肾脏病进展模型。
Ren Fail. 2024 Dec;46(2):2406402. doi: 10.1080/0886022X.2024.2406402. Epub 2024 Oct 21.
8
Role of Estimated Glomerular Filtration Rate in Clinical Research: The Never-Ending Matter.估算肾小球滤过率在临床研究中的作用:永无止境的问题。
Rev Cardiovasc Med. 2024 Jan 4;25(1):1. doi: 10.31083/j.rcm2501001. eCollection 2024 Jan.
9
Kidney trajectory charts improve GP management of patients with reduced kidney function: a randomised controlled vignette study.肾脏轨迹图改善全科医生对肾功能减退患者的管理:一项随机对照病例 vignette 研究。
BJGP Open. 2024 Jul 29;8(2). doi: 10.3399/BJGPO.2023.0193. Print 2024 Jul.
10
Mathematical expansion and clinical application of chronic kidney disease stage as vector field.将慢性肾脏病分期拓展为向量场的数学模型及其临床应用
PLoS One. 2024 Mar 13;19(3):e0297389. doi: 10.1371/journal.pone.0297389. eCollection 2024.
主观整体营养评估、透析质量与肾脏病实践中的科学方法理论。
Artif Organs. 2020 Oct;44(10):1021-1030. doi: 10.1111/aor.13762. Epub 2020 Jul 27.
4
A Review of Specific Biomarkers of Chronic Renal Injury and Their Potential Application in Nonclinical Safety Assessment Studies.慢性肾损伤特异性生物标志物的研究进展及其在非临床安全性评价研究中的潜在应用。
Toxicol Pathol. 2021 Jul;49(5):996-1023. doi: 10.1177/0192623320985045. Epub 2021 Feb 12.
5
Pro-inflammatory cytokines as potential predictors for intradialytic hypotension.促炎细胞因子作为透析中低血压的潜在预测因子。
Ren Fail. 2021 Dec;43(1):198-205. doi: 10.1080/0886022X.2021.1871921.
6
Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review.慢性肾脏病患者肠道菌群的特定改变:一项更新的系统评价。
Ren Fail. 2021 Dec;43(1):102-112. doi: 10.1080/0886022X.2020.1864404.
7
Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated.慢性肾脏病预后和实践模式研究中3-5ND期慢性肾脏病患者的贫血和缺铁情况:常未得到检测,治疗方式各异
Clin Kidney J. 2019 Aug 3;13(4):613-624. doi: 10.1093/ckj/sfz091. eCollection 2020 Aug.
8
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用:EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.
9
A multicenter study of malnutrition status in chronic kidney disease stages I-V-D from different socioeconomic groups.一项来自不同社会经济群体的慢性肾脏病 I-V-D 期营养不良状况的多中心研究。
Saudi J Kidney Dis Transpl. 2020 May-Jun;31(3):614-623. doi: 10.4103/1319-2442.289448.
10
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.达格列净对非糖尿病慢性肾脏病患者蛋白尿的影响(DIAMOND):一项随机、双盲、交叉试验。
Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593. doi: 10.1016/S2213-8587(20)30162-5.